FEELM and RELX international Launch First Whole Chain Recycling Scheme for Disposable Vapes in the UK
22.5.2023 14:53:00 EEST | Business Wire | Press release
World leading closed system solution provider FEELM has joined forces with leading vaping brand RELX to launch the UK vape industry’s first whole-chain recycling scheme for single use devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005354/en/
FEELM Cooperates with RELX for the first industrial whole chain recycling scheme
The initiative aims to address the growing concerns surrounding single use products being thrown away by consumers and the environmental impact caused by them ending up in landfill.
It follows estimates from independent non-profit organization Material Focus that 1.3 million single use vape devices are discarded each week in the UK which, taken over a year, contain enough lithium to power 1,200 electric vehicles.
Also, based on market research by Opinium, around 168 million disposable vapes are bought annually in the UK, with half of those being thrown out with regular waste rather than being disposed of in a waste electricals recycling bin or being returned to the retailer.
This new initiative will see FEELM, the flagship brand of inhalation tech company SMOORE, team up with leading single use vape provider RELX to implement sustainability strategies which will benefit both their business partners, customers and the wider community.
The initiative involves a household collection system, a transparent recycling process and retailer partnerships to make it as easy as possible for consumers to participate.
Consumers can send their used vapes to FEELM either through pre-paid postage labels downloaded online or by visiting one of the retail partners. The household collection system simplifies the recycling process, making it more accessible to a broader audience.
To encourage consumers to participate in the recycling scheme, FEELM plans to introduce an incentive mechanism that boosts consumer engagement. For every ten used devices sent back, RELX provides a brand new RELX Magic Go disposable vape with FEELM Max technology. The FEELM Max boasts impressive performance and sets a new TPD-compliant industry benchmark, offering 800 puffs with its 2 ML capacity.
By fostering a recycling mindset and strengthening education around recycling, the company aims to create a more environmentally conscious community that actively participates in sustainable practices.
By offering a comprehensive and convenient recycling method, FEELM and RELX hope to raise the environmental awareness of end users, inspire trust in the recycling system and encourage consumers to play their part in helping protect the environment.
Delivering the Social Responsibility
Commenting on the recycling scheme, Johnny Zhang, Assistant President at FEELM said: “We firmly believe that disposables have a critical part to play in helping the UK achieve its smokefree aspirations. The industry needs to do much more in the environmental department, but it is starting to make headway.
“Our green innovation program is well underway, but we are now ramping it up significantly to ensure we don’t just help protect adult smokers’ lives but also the planet too.
“This commitment to making recycling more accessible demonstrates our dedication to corporate social responsibility and environmental sustainability. As this initiative gains traction, we hope it will serve as a model for other industries looking to implement eco-friendly practices and engage adult customers in their sustainability efforts.”
Chris Aikens, Senior External Affairs Manager for Europe at RELX International, said: “We are pleased to be working with SMOORE on this project which highlights our commitment to the long-term sustainability of disposable devices. These products provide a useful tool to enable adult smokers to make the switch from combustible cigarettes and their full potential needs to be recognised. This recycling scheme will benefit both the planet and adult consumers.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005354/en/
Contact information
Ruiqi Wang
ruiqi.wang@smooretech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
